Even just a few years ago, conventional wisdom held that “innovation” and “operations” didn’t belong in the same sentence. Performance targets ruin the creative impulse. Science needs space, time, and freedom to flourish. Innovation can never be bottled into an efficient, machine-like operation. Read More

In this third instalment of his series of opinion pieces, enterprise investment specialist Chris Potts suggests that flexibility and speed-to-outcomes can drive momentum and help make better choices. Read More

A carefully chosen and well-written hypothesis makes it easy to design an experiment to test and learn from. So here are six steps to follow when crafting your prediction. Read More

Healthcare, like many other fields, is an increasingly collaborative industry, with most organizations looking outside their internal silos for new ideas, innovations, and expertise. As we’ve highlighted in other works, co-patenting—when two or more parties collaborate to obtain a patent—has risen... Read More

In the latest in his series of opinion pieces, enterprise investment specialist Chris Potts suggests the Airbus A380 is a case in point of how investing in change is about working with diverse probabilities of success. Read More

Returning to The Lean Startup for reference, we explore the idea of experimentation in the innovation process and focus on one particular form of experiment: the Minimum Viable Product (MVP). Read More

In the first of a four-part opinion piece on 'Transforming ideas into outcomes at market-speed', enterprise investment specialist Chris Potts discusses how outcomes can come from a mix of different ideas. Read More

When most people think of IoT and construction, they will think about newly developed “smart homes” outfitted with security systems and a network of cameras. Or futuristic thermostats with the ability to learn from patterns of behavior and adjust the temperature automatically. However, most of... Read More

Taking EasyJet as an example, we look at the concept first described by Joseph Bower and Clayton Christensen in 1995, and how it differs from radical or transformational innovation. Read More

There’s a repeated conversation that happens among corporate leaders, whispered in the halls of conferences and passed among friends like a rite of passage: “Watch out for the corporate antibodies,” goes the refrain. “They’ll kill your innovations faster than anything else.” Read More